ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

1000 Pediatric Kidney Transplants-A Single Center Experience

S. Chinnakotla, B. Chavers, P. Verghese, M. Rheault, C. Najera, T. Nevins, C. Kashtan, M. Mauer, K. Gillingham, J. Najarian, A. Matas

Surg, U Mn, Mpls, MN
Ped Nephrol, U Mn, Mpls

Meeting: 2013 American Transplant Congress

Abstract number: C1419

Objective: To study outcomes and risk-factors for graft-loss in > 1000 pediatric kidney transplants.

Methods: We studied outcomes by immunosuppression era: I) 1963-83 (ATG, Imuran and steroids); II) 1984-2001 (introduction of CNIs); and III) 2001-present (steroid avoidance).

Results: 1010 transplants (Age<1yr=53, 1-2yr=124, 3-5yr=182, 6-10yr=216, 11-18=435) were done. (810 Ist; 200 retx) (LD=69%, DD=31%; 3% LURDs pre-2001, 17% since [p<.01]). Congenital-anomalies were the commonest indication (Table 1) Ten-yr actuarial patient-survival (p <0.001), graft survival (p=0.0005), and death-censored graft-survival (p=.02) steadily improved by era (Table 1). Graft half-life (starting @ 1 yr posttx) is 33 years for LDs, 14 years for DDs. Graft-loss for all causes < 1 year posttx has ⇓ by era (Table 1); from 1-5 yrs, CR/IFTA remains predominant. For the entire cohort, by multivariate-analysis, LD(p<.0001) and Era III (vs I and II) (p<.0003) had better survival.↑ LD donor age did not affect graft survival.Risk-factors for loss varied by era (Table 2). Successful transplant was associated with improved QoL, and return-to-school and (subsequently) work.

Conclusions: Long term Outcomes of pediatric renal transplantation have continued to improve. LD grafts provide the most benefit and should be the first option.

<

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Chinnakotla S, Chavers B, Verghese P, Rheault M, Najera C, Nevins T, Kashtan C, Mauer M, Gillingham K, Najarian J, Matas A. 1000 Pediatric Kidney Transplants-A Single Center Experience [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/1000-pediatric-kidney-transplants-a-single-center-experience/. Accessed May 20, 2025.

« Back to 2013 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences

Table 1
  Era I 1963-1983 (n=362) Era II 1984-2001 (n=451) Era III 2001-2012 (n=197)
Indication for Transplant
Congenital Anomalies 60(17%) 95(21%) 52(26%)
Obstructive Nephropathy 52(15%) 81(18%) 28(20%)
Congenital Nephrotic Syndrome 34(9.4%) 36(8%) 9(5%)
FSGS Steriod Resistan 23(6%) 35(7%) 23(11%)
GN-CGN 53(15%) 7(1.5%) 0
10-Year Patient Survival (%)
LD 76 92 94
DD 66 94 100
10-Year Graft Survival (%)
LD 49 65 75
DD 31 43 57
Causes of Graft Loss < 1 Year (%)
Acute Rejection 8 2 0.6
Chronic Rejection/CAN 5 1 0.6
Recurrence 2 2 1
Technical/Thrombosis 3 4 2
DWF 5 1 1
Functioning 75 88 95
Causes of Graft Loss 1-5 Years (%)
Acute Rejection 0.7 0.8 2
Chronic Rejection/CAN 14 10 6
Recurrence 2 2 1
Non Compliance 0.4 2 2
DWF 6 1 2